Researchers led by a team at Tel Aviv University have found that genetic variants involved in the innate immune response are strongly linked to the onset of breast cancer (BC) in risk carriers. BRCA1 genetic modification. The team performed whole exome sequencing (WES) of hundreds of Ashkenazi Jewish women in BRCA1 different risk, and found that the strongest correlation with the earlier onset of BC were genes involved in the activation of natural killer (NK) cells, which act as the body’s rapid defense against viruses and cancer.
The findings prompt researchers to suggest that more refined, individualized models for mutation carriers may be needed. BRCA1 Although this genetic mutation increases their risk of developing breast cancer, the age of diagnosis varies greatly.
The team reported the findings on Journal of Medical Geneticsin a paper titled “Disruptive variants of immune genes are associated with earlier onset of breast cancer. BRCA1 185delAG carriers,” where they concluded “To our knowledge, our study is the first large-scale WES analysis aimed at identifying BC risk genes in BRCA1 PV carriers … Our findings highlight a new role for innate immune mechanisms as potential modifiers of BC risk in BRCA1 bearers.”
BRCA1 is one of the two most prominent breast cancer genes, the authors explained. “Women with pathogenic type (PV) in BRCA1 they have an estimated 60-80% lifetime risk of developing BC, as well as a very high risk (30-40%) of ovarian cancer.
Surgical removal of the breasts, arteries and ovaries reduces the risk, but because the age at which breast cancer develops in carriers varies widely, even among those with the same genetic makeup. BRAC1 Change, it is difficult to know when this life-changing procedure should be done, they suggested. “Although the intervention in BC is BRCA1 High carriers, not limited, and years in BC to be evaluated among BRCA1 carriers vary greatly, even among carriers of the same PV in the same household. ”
This difference in disease onset suggests that other variables may play a role, including immunosuppression, because of the important role the immune system plays in developing and guarding against cancer, the team suggested. They hypothesized that “…immune function may also modulate BC risk among BRCA1 PV carriers. ”
To test this further, the team studied detailed information from 321 Ashkenazi Jewish women, among whom the prevalence of BRCA1 The genes are five to six times higher than other races around the world. The women were all carrying the same thing BRCA1 mutation (185delAG) and 98 of them were diagnosed with breast cancer. Their average age at diagnosis was 41.5 years, but ranged from 26 to 75 years. “Using a large whole-exome sequencing (WES) cohort of Israeli pregnant women BRCA1 185delAG AJ founder of PV, we examined whether carrying some deleterious variants of genes involved in specific arms of the immune system was associated with age at BC diagnosis,” they commented.
Whole exome sequencing reads the most important 1-2% of human DNA—the exome—which contains about 85% of the mutations known to cause certain health conditions. The researchers’ exome sequencing data revealed that some potentially harmful mutations (variants) in genes involved in immunity were significantly associated with the onset of breast cancer.
Mutations in genes involved in natural killer cell activation were significantly associated with earlier onset of disease, increasing the risk by 3.5 times. They said: “We found that the presence of variants that cause damage to genes associated with innate immunity is significantly associated with earlier BC diagnosis.” “This effect was observed for several groups of circulating genes; the strongest was that of expressed genes involved in NK cell activation.” They have shown that the effect of changing the risk they are surrounded by is specific to the genes involved in immunity. There was no significant relationship identified for genes related to the immune system.
“In general, what we found in the Israeli group is the same BRCA1 PV carriers highlight a potential role for innate immune mechanisms as changes in BRCA1 intervention and may support the development of more refined, individualized BC risk prediction models for BRCA1 The researchers wrote.” However, they warned, “It remains to be determined whether these preliminary studies can be carried out in independent, heterogeneous, larger groups of carriers of different PVs. BRCA1.”
#Immune #Gene #Mutations #Linked #Early #Breast #Cancer #BRCA1 #Carriers